Sano Genetics/X
Jul 31, 2025, 15:37
Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
Sano Genetics shared an inviting post on X:
”Tune in to Episode 198 of The Genetics Podcast.
This week, we’re joined by Benny Sorensen, CEO of Hemab Therapeutics. Tune in to hear about how Benny’s persistence and “unreasonable” leadership led to Hemab’s first program, how Hemab is reimagining clotting therapies by centering patient voices, and the value of their multi-modality and collaborative approach.”
Listen to the Apple Podcast here.
Listen to the YouTube Podcast here.
Stay tuned with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring